Xanthinol niacinate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 341315

CAS#: 437-74-1

Description: Xanthinol niacinate is a combination of xanthinol and niacin which acts as a vasodilator. Studies show that Xanthinol niacinate can modulate tumors during their reoxygenation. Xanthinol niacinate also displays anti-platelet and thrombolytic activity. In addition, this compound can reduce whole blood viscosity, as a result of its anti-platelet activity and decrease cholesterol and fibrinogen.


Price and Availability

Size
Price

Size
Price

Size
Price

Xanthinol niacinate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 341315
Name: Xanthinol niacinate
CAS#: 437-74-1
Chemical Formula: C19H26N6O6
Exact Mass: 434.1914
Molecular Weight: 434.453
Elemental Analysis: C, 52.53; H, 6.03; N, 19.34; O, 22.10


Synonym: Xanthinol niacinate; NSC 113217; NSC-113217; NSC113217.

IUPAC/Chemical Name: Nicotinic acid, compd. with 3,7-dihydro-7-(2-hydroxy-3-((2-hydroxyethyl) methylamino)propyl)-1,3-dimethyl-1H-purine-2,6-dione

InChi Key: GEPMAHVDJHFBJI-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)

SMILES Code: Cn1c2c(c(=O)n(c1=O)C)n(cn2)CC(CN(C)CCO)O.c1cc(cnc1)C(=O)O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Bai X, Huang L, Hu K, Qu F. Inhibited proliferation of human umbilical artery smooth muscle cells by xanthinol nicotinate. Med Biol Eng Comput. 2016 Jun;54(6):891-8. doi: 10.1007/s11517-015-1438-9. Epub 2015 Dec 30. PubMed PMID: 26718554.

2: Živić L, Živić D, Djonović N. [Sudden hearing loss: our experiences in treatment with vasoactive and corticosteroid therapy]. Srp Arh Celok Lek. 2012 Mar-Apr;140(3-4):153-8. Serbian. PubMed PMID: 22650099.

3: Kuznetsov MR, Rodionov SV, Koshkin VM, Virganskiĭ AO, Golosnitskiĭ PIu, Tepliakov SA, Kosykh IV, Ostapchuk NA, Lisenkov OP, Chernikov VP. [Role of low-dose acetylsalicylic acid in comprehensive postoperative treatment of patients with lower-limb chronic arterial insufficiency]. Angiol Sosud Khir. 2011;17(2):23-9. Russian. PubMed PMID: 21983458.

4: Kovalev VA, Karaguzhin SK, Abdulkhamidov AN, Danovich VM, Kyzlasov PS, Matskevich SV. [Peyronie's disease: comparative results of conservative treatment]. Urologiia. 2010 Nov-Dec;(6):40-4. Russian. PubMed PMID: 21427993.

5: Segers J, Crokart N, Danhier P, Grégoire V, Jordan BF, Gallez B. Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors. Int J Cancer. 2010 Jan 15;126(2):583-8. doi: 10.1002/ijc.24724. PubMed PMID: 19585554.

6: Kucherov II, Rytik PG, Podol'skaya IA, Mistryukova LO, Korjev MO. Novel inhibitors of HIV discovered among existing classes of pharmaceutical compounds indicated for unrelated clinical indications. Curr Pharm Des. 2009;15(11):1187-90. Review. PubMed PMID: 19355959.

7: Zivić L, Zivić D, Stojanović S. [Sudden hearing loss--our experience in treatment with vasoactive therapy]. Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):91-4. Serbian. PubMed PMID: 18720739.

8: Liu HQ, Su MX, Di B, Hang TJ, Hu Y, Tian XQ, Zhang YD, Shen JP. Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of xanthinol in human plasma and its application in a bioequivalence study of xanthinol nicotinate tablets. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 15;873(1):20-6. doi: 10.1016/j.jchromb.2008.07.045. Epub 2008 Aug 7. PubMed PMID: 18718822.

9: Miller DA. [Pathogenetic basis for using prodectin and teonicol, redergin and aescuzan in complex treatment of chronic gastritis]. Eksp Klin Gastroenterol. 2002;(3):22-5, 118. Russian. PubMed PMID: 12353381.

10: Rosina P, Chieregato C, Miccolis D, D'Onghia FS. Psoriasis and side-effects of mesotherapy. Int J Dermatol. 2001 Sep;40(9):581-3. PubMed PMID: 11737454.

11: Pospísilová M, Jokl V, Dolejsová J. [Determination of xanthinol nicotinate in drug preparations using capillary isotachophoresis]. Ceska Slov Farm. 2000 Mar;49(2):88-90. Czech. PubMed PMID: 10953450.

12: Bieroń K, Swies J, Kostka-Trabka E, Gryglewski RJ. Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms. J Physiol Pharmacol. 1998 Jun;49(2):241-9. PubMed PMID: 9670107.

13: Basinskiĭ SN, Krasnogorskaia VN. [New method of atherosclerotic macular dystrophies treatment]. Vestn Oftalmol. 1997 Nov-Dec;113(6):17-9. Russian. PubMed PMID: 9483992.

14: Lehmann E, Klieser E. Drug monitoring studies as a method of analyzing response criteria. Pharmacopsychiatry. 1997 Jan;30(1 Suppl):52-6. PubMed PMID: 9035228.

15: Kolesnyk MO, Lapchyns'ka II. [The efficacy of using antiaggregants in chronic glomerulonephritis with grade-I chronic kidney failure]. Lik Sprava. 1996 Jan-Feb;(1-2):135-7. Ukrainian. PubMed PMID: 9005074.

16: Fursova ZK, Balika IuD, Mamedalieva NM, Razumovskaia IN. [Characteristics of lymphocytic enzyme status of the newborn after metabolic therapy of pregnant women]. Akush Ginekol (Mosk). 1995;(4):26-8. Russian. PubMed PMID: 7485755.

17: Skarzynski D, Kotwica J. Mechanism of noradrenaline influence on the secretion of ovarian oxytocin and progesterone in conscious cattle. J Reprod Fertil. 1993 Mar;97(2):419-24. PubMed PMID: 8388956.

18: Lehmann E, van der Crone L, Grobe-Einsler R, Linden M. Drug monitoring study (phase IV) of xantinolnicotinate (Complamin) in general practice. Pharmacopsychiatry. 1993 Mar;26(2):42-8. PubMed PMID: 8378412.

19: Anderer P, Barbanoj MJ, Saletu B, Semlitsch HV. Restriction to a limited set of EEG-target variables may lead to misinterpretation of pharmaco-EEG results. Neuropsychobiology. 1993;27(2):112-6. PubMed PMID: 8515827.

20: Vesel'skiĭ ISh, Gritsaĭ NN. [The correction of lipid peroxidation metabolism, the hemostatic system and cerebral hemodynamics in patients with the initial manifestations of cerebral circulatory insufficiency]. Lik Sprava. 1992 Jul;(7):50-2. Russian. PubMed PMID: 1448987.